tiespectus
AssetAlso MK-8748
Inhibits vascular endothelial growth factor to reduce retinal vascular permeability and edema
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- VEGFA
- 6
- Indications
- 3
- Trials
- 2
- Developers
Indications
6Diabetic retinopathy
Phase 3, Recruiting, NCT07705555, clinicaltrials.gov, 7 Oct 2026
Macular edema
Phase 3, Recruiting, NCT07705555, clinicaltrials.gov, 7 Oct 2026
Age-related macular degeneration
Phase 2, Recruiting, NCT07440225, clinicaltrials.gov, 7 Oct 2026
3 more
In the full profile
- Targets and what it contains1
- Owner and partners2
- Trials3
- Evidence for its targets1
- Competitors12
- Signals3
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026, 3 sources